Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Joint Provisional Liquidators appointed) (For restructuring purposes only) (Incorporated in the Cayman Islands with limited liability) (Stock Code: 8088)

SUPPLEMENT ANNOUNCEMENT TO THE 2019 ANNUAL REPORT

Reference is made to the annual report for the year ended 31 December 2019 ("2019 Annual Report") of AID Life Science Holdings Limited (the "Company" and, together with its subsidiaries, the "Group") published on 11 May 2020. Capitalised terms used in this announcement shall have the same meanings as those defined in the 2019 Annual Report unless otherwise defined herein.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to supplement the following information to the Management Discussion and Analysis and intangible assets disclosed on pages 3–11 and pages 132–134 of the 2019 Annual Report respectively.

1. INVESTMENT IN FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

The investment cost of Zoox is US\$30,000,000 (equivalent to approximately HK\$234,000,000), there is no dividend received from Zoox since the investment.

The face value of the convertible bond of China Creative is HK\$50,000,000, and the fair value at the date of initial recognition of the convertible bonds is HK\$61,239,000.

2. IMPAIRMENT LOSS ON GOODWILL OF HGGL GROUP

The goodwill in HGGL Group arose from the acquisition of it for its mobile games business, with the latter being considered as a lowest level single cash-generating unit ("CGU") due to the individual assets of HGGL Group does not generate cash inflows that are largely independent to other assets, and the value in use of the individual assets of HGGL Group cannot be estimated to be close to its fair value less costs of disposal. The Company has considered the recoverable amount of the CGU is the value in use of HGGL Group, and the fair value less cost of disposal approximate to the value in use,

provided that potential buyer, if any, of HGGL Group shall consider the value in use as a basis of bid price. The value in use is determined as the cash flow projections on reasonable and supportable assumptions that represent management's best estimate of the range of economic conditions that exist over the remaining useful life of the asset. In terms of the key assumptions used for value in use calculations, there is no change in between 2018 and 2019.

Save for the information above, the contents of the 2019 Annual Report remain unchanged.

By Order of the Board **AID Life Science Holdings Limited** (Joint Provisional Liquidators appointed) (For restructuring purposes only) **Chan Suet Ngan** Executive Director

Hong Kong, 27 August 2020

As at the date of this announcement, the Directors are:

Executive Directors:

Chan Suet Ngan and Hu Kenneth

Independent Non-Executive Directors:

Yuen Kwok On, Yau Chung Hang and Ip Wing Wai

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement in this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the "Latest Company Announcements" page for at least 7 days from the date of its posting and on the website of the Company at www.8088inc.com.